Reports Q4 revenue $548.9M, consensus $545.73M. Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “We exited 2023 with growing momentum driven by record contract wins for the year in our healthcare business, important FDA clearances for innovative new products and strong growth in our hearables business. Our ability to translate our core technologies into products that deliver better outcomes for consumers, patients, and providers continues to be the engine for our long-term growth across all our businesses. With stabilization of hospital census and operations post pandemic, our healthy contract backlog and our cutting-edge innovations in growing markets, Masimo is well-positioned for 2024.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MASI:
- Masimo price target raised to $117 from $70 at Piper Sandler
- MASI Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Masimo Corp Announces Board Reshuffle and Director Resignation
- Masimo announces FDA-cleared ‘over-the-counter’ fingertip pulse oximeter
- What Wall Street experts are saying about Apple ahead of earnings